Date

Headline

PDF

11/12/2013
Appendix 3B
05/12/2013
Company Update
19/11/2013
Reinstatement to Offical Quotation
19/11/2013
Response to ASX Appendix 3Z Query
18/11/2013
ASX Circular – Reinstatement to Official Quotation
18/11/2013
Reinstatement to Official Quotation – 19 November 2013
14/11/2013
Pre-quotation disclosures
14/11/2013
Retirement of Deed Administrator
14/11/2013
Annual Report for the Year Ended 30 June 2013
14/11/2013
Half Yearly Report for the period ended 31 December 2012
14/11/2013
Annual Report for the Year Ended 30 June 2012
13/11/2013
Administrator/Receiver ??? Appointed/Removed
29/10/2013
Change of Director’s Interest Notices
29/10/2013
Final Director’s Interest Notices
25/10/2013
Completion of Recapitalisation Proposal
21/10/2013
Company Secretary Appointment/Resignation
25/09/2013
Appendix 3B
19/09/2013
Prospectus
03/09/2013
Announcement of Updated Constitution
03/09/2013
Header Corr: Consolidation process as approved by Sh’holders
03/09/2013
Announcement of New Board/Appendix 3X Notices
03/09/2013
Internal
02/09/2013
Results of Meeting
30/07/2013
Details of Share Registry address
30/07/2013
Notice of General Meeting
28/02/2013
Company Administration – Other

Date

Headline

PDF

02/12/2014
Change of Company Name
28/11/2014
Results of Meeting – 2014
28/11/2014
Results of Meeting – 2013 meeting
28/11/2014
Results of Meeting – 2012 meeting
28/11/2014
VHL boosts leadership with key chair and board appointments
07/11/2014
Virax Shareholder Newsletter
03/11/2014
Annual Report to shareholders
03/11/2014
Appendix 4C – quarterly
31/10/2014
ASX Grants Waiver – Listing Rule 10.13.3
30/10/2014
Company overview brochure
30/10/2014
Notice of AGM, including Independent Experts Report
29/10/2014
Notice of Annual General Meeting/Proxy Form
29/10/2014
Notices of AGM in relation to the 2012 and 2013 years
28/10/2014
Roadshow Presentation
17/10/2014
Video Presentation with Managing Director
17/10/2014
VHL TO ACQUIRE DEEP AKT INHIBITOR PORTFOLIO
15/10/2014
Trading Halt Request
15/10/2014
Trading Halt
23/09/2014
Multiple Myeloma Authority Joins Scientific Advisory Board
09/09/2014
FDA IND Re-Activation Request for Phase Ib/II Trial
01/09/2014
Virax Holdings Appendix 4E and 2014 Financial Report
31/07/2014
Appendix 4C – quarterly
23/07/2014
Investor Roadshow Presentation
21/07/2014
Cancer Authority to help Steer US Breast Cancer Progam
24/06/2014
Initial Director’s Interest Notice
23/06/2014
VHL appoints Ground Zero Pharmaceuticals
16/06/2014
New MD to Present at International Life Sciences Showcase
06/06/2014
Initial Director’s Interest Notice
30/05/2014
VHL completes Pathway acquisiton, appoints new director
30/05/2014
Appendix 3B
20/05/2014
Appendix 3B
15/05/2014
Appointment of Managing Director to Drive Cancer Programs
15/05/2014
Appendix 3B
14/05/2014
Disclosure Document
09/05/2014
Capital Raising Update
09/05/2014
Results of Meeting
09/05/2014
Chairman’s Address at General Meeting
06/05/2014
Investor Newsletter
05/05/2014
Virax Option to Acquire Exclusive Worldwide Licence
01/05/2014
Trading Halt
30/04/2014
Appendix 4C – quarterly
29/04/2014
Appointment of Gene Tech expert to further develop assets
24/04/2014
Co-X-Gene Development Pipeline
08/04/2014
Notice of General Meeting/Proxy Form
03/04/2014
ASX Grants Waivers – Listing Rule 7.3.2
27/03/2014
Appendix 3B
25/03/2014
Virax secures $3 million placement
21/03/2014
Trading Halt
17/03/2014
Investor presentation
17/03/2014
Virax to acquire advanced cancer platform from Yale Uni
14/03/2014
Trading Halt
28/02/2014
Half Yearly Report and Accounts
19/02/2014
Intellectual Property Report Update
18/02/2014
Appendix 3B
12/02/2014
Response to ASX Aware Letter
07/02/2014
Transgene Announces Topline Preliminary Results

Date

Headline

PDF

01/12/2015
Investor Presentation – December 2015
30/11/2015
H. Lee Moffitt Cancer Center Leukaemia Oncologist Joins SAB
26/11/2015
MD Anderson Leukemia Expert Joins PTX SAB
25/11/2015
Additional Placement Raises $1.0 million
23/11/2015
Share Purchase Plan Completion
20/11/2015
Release of Securities from Escrow
18/11/2015
Share Purchase Plan Results
09/11/2015
PTX Shareholder Newsletter
04/11/2015
Results of Meeting
02/11/2015
Share Purchase Plan – Documentation issued to shareholders
30/10/2015
September 2015 Appendix 4C – Quarterly
29/10/2015
Cleansing Notice – Share Purchase Plan
29/10/2015
Share Purchase Plan Offer Document
29/10/2015
Share Purchase Plan Fully Underwritten up to target amount of $1.03 million
15/10/2015
Final Directors Interest Notice
15/10/2015
Executive Management Change
05/10/2015
Notice of Annual General Meeting and Proxy Form
01/09/2015
CSO named among Top 20 Translational Researchers by Nature
31/08/2015
Two new Patents granted to Protect Lead Asset PTX-200
26/08/2015
PTX-200 Phase 1B/2 Clinical Trial Update
21/08/2015
Proposed Grant of Options to Non-Executive Directors
12/08/2015
Prescient Shareholder Newsletter
29/06/2015
IND for Phase 1b/2 Ovarian Cancer Trial Transferred to Prescient
23/06/2015
PTX Issues shares for Milestone 1 – Pathway Acquisition
10/06/2015
US FDA Reactivates PTX’s IND for PTX-100 Breast Cancer Trial
26/05/2015
Distinguished Moffitt Cancer Center Scientist Appointed CSO
28/04/2015
Prescient Appoints Chief Medical Officer
21/04/2015
Encouraging Pre-Clinical Data Presented at US Cancer Meeting
01/04/2015
Approval received to transfer IND Sponsorship for PTX
09/02/2015
Prescient Therapeutics Acquires Exclusive Worldwide License for Cancer Biomarker p27
23/02/2015
Prescient Therapeutics Granted Key U.S. Patents
03/03/2015
PTX to Present at 27th Annual Roth Conference

Date

Headline

PDF

16/12/2016
Change of Registry Address
14/12/2016
First Patient Dosed on Phase 1b/2 AML Trial
08/12/2016
Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
30/11/2016
Results of Annual General Meeting
02/11/2016
Receipt of R&D Tax Rebate
28/10/2016
Notice of Annual General Meeting/Proxy Form
28/10/2016
September 2016 Appendix 4C – Quarterly
26/09/2016
First Patient at Moffitt dosed in Phase 1b/2 breast trial
13/09/2016
Rodman & Renshaw Global Investment Conference Presentation
13/09/2016
PTX presents at Rodman & Renshaw Investment Conference
31/08/2016
Appendix 4G and Corporate Governance Statement
31/08/2016
Appendix 4E and 2016 Annual Report
04/08/2016
USPTO Grants Allowances for Two PTX-200 Patents
20/07/2016
Change to Exercise Price of Options
20/07/2016
Amended Share Trading Policy
20/07/2016
June 2016 Appendix 4C – Quarterly
12/07/2016
Shortfall Placement Oversubscribed
30/06/2016
Completion of Entitlement Issue Allotment and Appendix 3B
29/06/2016
Entitlement Offer Closure and Shortfall Notification
23/06/2016
Tranche 2 Capital Raising Complete and Appendix 3B
22/06/2016
Results of Meeting
16/06/2016
Extension of Closing Date of Entitlement Offer
15/06/2016
Yale Joins PTX’s Phase 1b/2 AML Clinical Trial
06/06/2016
Despatch of Pro-rata Rights Issue Offer Document
03/06/2016
Replacement Entitlement Offer Prospectus
01/06/2016
Rights Issue Update
24/05/2016
Tranche 1 Capital Raising Complete
23/05/2016
Notice of General Meeting/Proxy Form
18/05/2016
Letter to Optionholders
18/05/2016
Letter to Ineligible shareholders
18/05/2016
Letter to Eligible Shareholders
18/05/2016
Appendix 3B
18/05/2016
Offer Document
18/05/2016
PTX Secures $7.0M Capital Raising
21/04/2016
March 2016 Appendix 4C – Quarterly
13/04/2016
Investor Presentation – April 2016
31/03/2016
RedChip Issues Research on Prescient Therapeutics
03/03/2016
Edison Investment Research Initiates Coverage
02/03/2016
PTX Featured on Bloomberg’s – The Redchip Money Report
17/02/2016
PTX-200 Breast Cancer Trial Progresses
15/02/2016
Steven Yatomi-Clarke Appointed CEO
21/01/2016
PTX Presents at NobleCon12
14/01/2016
Yale Hematolgy Leader Joins PTX Scientific Advisory Board
11/01/2016
PTX to present at Biotech Showcase 2016 in San Francisco
08/01/2016
FDA Allows PTX IND for Leukemia Phase Ib & II Trials

Date

Headline

PDF

16/03/2017
Three Additional US Patents Granted
15/03/2017
ROTH Conference Presentation
15/03/2017
PTX presentation for 29th Annual ROTH Conference
08/03/2017
First Cohort Successfully Completed in Phase 1b/2 AML Trial
03/03/2017
PTX to present at 29th Annual Roth Conference
23/02/2017
Appendix 4D and Half Year Financial Report
25/01/2017
December 2016 Appendix 4C – Quarterly
11/01/2017
Investor Presentation January 2017
11/01/2017
PTX to present at Biotech Showcase 2017 in San Francisco